These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28346841)

  • 21. High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.
    Siljic M; Salemovic D; Cirkovic V; Pesic-Pavlovic I; Todorovic M; Ranin J; Dragovic G; Jevtovic D; Stanojevic M
    Intervirology; 2017; 60(1-2):43-47. PubMed ID: 28772259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
    Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
    Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Xi P; Wang H; Zhong Z; Liu S; Tang J; Guo C; Dai P
    Pharmacogenomics; 2022 Oct; 23(15):835-845. PubMed ID: 36169168
    [No Abstract]   [Full Text] [Related]  

  • 24. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay.
    Loubser S; Paximadis M; Gentle N; Puren A; Gray CM; Tiemessen CT
    Tissue Antigens; 2014 Oct; 84(4):389-97. PubMed ID: 25154892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.
    Zubiaur P; Saiz-Rodríguez M; Villapalos-García G; Navares-Gómez M; Koller D; Abad-Santos F
    Pharmacogenet Genomics; 2021 Apr; 31(3):53-59. PubMed ID: 33044391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
    Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
    Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
    Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
    Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.
    Daly AK
    Curr Drug Metab; 2014 Feb; 15(2):196-201. PubMed ID: 24694233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
    Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
    Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
    [No Abstract]   [Full Text] [Related]  

  • 32. A new approach to safely type for HLA the HIV infected people eligible to abacavir therapy: saliva or buccal swab as reliable DNA sources.
    Badulli C; Sbarsi I; Di Giorgio D; Mantovani M; Maserati R; Barbarini G; Salvaneschi L; Martinetti M
    Clin Chim Acta; 2011 Oct; 412(21-22):1995-8. PubMed ID: 21767530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.
    Dello Russo C; Lisi L; Fabbiani M; Gagliardi D; Fanti I; Di Giambenedetto S; Cauda R; Navarra P
    Pharmacogenomics; 2014 Feb; 15(3):319-27. PubMed ID: 24533711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
    Small CB; Margolis DA; Shaefer MS; Ross LL
    BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.
    Hammond E; Mamotte C; Nolan D; Mallal S
    Tissue Antigens; 2007 Jul; 70(1):58-61. PubMed ID: 17559582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
    Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
    AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus typing by single tube multiplex amplification in real time (SMART): the PapillomaFinder® SMART 20 assay.
    Ossel J; Litjens RJ; Reijans M; Brink AA; Ummelen M; Ramaekers FC; Hopman AH; Simons G
    J Clin Virol; 2014 Dec; 61(4):540-7. PubMed ID: 25453331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 39. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
    Giardina E; Stocchi L; Foti Cuzzola V; Zampatti S; Gambardella S; Patrizi MP; Bramanti P; Pirazzoli A; Novelli G
    Electrophoresis; 2010 Oct; 31(21):3525-30. PubMed ID: 20925049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.